Your browser doesn't support javascript.
loading
Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase.
Ferré, Sergi; Bonaventura, Jordi; Zhu, Wendy; Hatcher-Solis, Candice; Taura, Jaume; Quiroz, César; Cai, Ning-Sheng; Moreno, Estefanía; Casadó-Anguera, Verónica; Kravitz, Alexxai V; Thompson, Kimberly R; Tomasi, Dardo G; Navarro, Gemma; Cordomí, Arnau; Pardo, Leonardo; Lluís, Carme; Dessauer, Carmen W; Volkow, Nora D; Casadó, Vicent; Ciruela, Francisco; Logothetis, Diomedes E; Zwilling, Daniel.
Afiliación
  • Ferré S; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, United States.
  • Bonaventura J; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, United States.
  • Zhu W; Circuit Therapeutics, Inc., Menlo Park, CA, United States.
  • Hatcher-Solis C; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, United States.
  • Taura J; Unitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Quiroz C; Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
  • Cai NS; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, United States.
  • Moreno E; Integrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, United States.
  • Casadó-Anguera V; Center for Biomedical Research in Neurodegenerative Diseases Network, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, Spain.
  • Kravitz AV; Center for Biomedical Research in Neurodegenerative Diseases Network, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, Spain.
  • Thompson KR; Eating and Addiction Section, Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Intramural Research Program, National Institutes of Health, Bethesda, MD, United States.
  • Tomasi DG; Circuit Therapeutics, Inc., Menlo Park, CA, United States.
  • Navarro G; Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, Intramural Research Program, National Institutes of Health, Rockville, MD, United States.
  • Cordomí A; Department of Biochemistry and Physiology, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
  • Pardo L; Laboratory of Computational Medicine, School of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
  • Lluís C; Laboratory of Computational Medicine, School of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
  • Dessauer CW; Center for Biomedical Research in Neurodegenerative Diseases Network, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, Spain.
  • Volkow ND; Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, United States.
  • Casadó V; Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, Intramural Research Program, National Institutes of Health, Rockville, MD, United States.
  • Ciruela F; Center for Biomedical Research in Neurodegenerative Diseases Network, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona, University of Barcelona, Barcelona, Spain.
  • Logothetis DE; Unitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Zwilling D; Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Front Pharmacol ; 9: 243, 2018.
Article en En | MEDLINE | ID: mdl-29686613
The central adenosine system and adenosine receptors play a fundamental role in the modulation of dopaminergic neurotransmission. This is mostly achieved by the strategic co-localization of different adenosine and dopamine receptor subtypes in the two populations of striatal efferent neurons, striatonigral and striatopallidal, that give rise to the direct and indirect striatal efferent pathways, respectively. With optogenetic techniques it has been possible to dissect a differential role of the direct and indirect pathways in mediating "Go" responses upon exposure to reward-related stimuli and "NoGo" responses upon exposure to non-rewarded or aversive-related stimuli, respectively, which depends on their different connecting output structures and their differential expression of dopamine and adenosine receptor subtypes. The striatopallidal neuron selectively expresses dopamine D2 receptors (D2R) and adenosine A2A receptors (A2AR), and numerous experiments using multiple genetic and pharmacological in vitro, in situ and in vivo approaches, demonstrate they can form A2AR-D2R heteromers. It was initially assumed that different pharmacological interactions between dopamine and adenosine receptor ligands indicated the existence of different subpopulations of A2AR and D2R in the striatopallidal neuron. However, as elaborated in the present essay, most evidence now indicates that all interactions can be explained with a predominant population of striatal A2AR-D2R heteromers forming complexes with adenylyl cyclase subtype 5 (AC5). The A2AR-D2R heteromer has a tetrameric structure, with two homodimers, which allows not only multiple allosteric interactions between different orthosteric ligands, agonists, and antagonists, but also the canonical Gs-Gi antagonistic interaction at the level of AC5. We present a model of the function of the A2AR-D2R heterotetramer-AC5 complex, which acts as an integrative device of adenosine and dopamine signals that determine the excitability and gene expression of the striatopallidal neurons. The model can explain most behavioral effects of A2AR and D2R ligands, including the psychostimulant effects of caffeine. The model is also discussed in the context of different functional striatal compartments, mainly the dorsal and the ventral striatum. The current accumulated knowledge of the biochemical properties of the A2AR-D2R heterotetramer-AC5 complex offers new therapeutic possibilities for Parkinson's disease, schizophrenia, SUD and other neuropsychiatric disorders with dysfunction of dorsal or ventral striatopallidal neurons.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2018 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2018 Tipo del documento: Article